WO1997007819B1 - Immunotherapy medicaments containing antibodies which specifically detect the mhcii antigen of a patient to be treated - Google Patents
Immunotherapy medicaments containing antibodies which specifically detect the mhcii antigen of a patient to be treatedInfo
- Publication number
- WO1997007819B1 WO1997007819B1 PCT/EP1996/003733 EP9603733W WO9707819B1 WO 1997007819 B1 WO1997007819 B1 WO 1997007819B1 EP 9603733 W EP9603733 W EP 9603733W WO 9707819 B1 WO9707819 B1 WO 9707819B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cells
- antigen
- receptor
- pharmaceutical composition
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract 18
- 108091007433 antigens Proteins 0.000 title claims abstract 18
- 102000036639 antigens Human genes 0.000 title claims abstract 18
- 239000003814 drug Substances 0.000 title claims abstract 7
- 238000009169 immunotherapy Methods 0.000 title claims 6
- 239000000203 mixture Substances 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000012636 effector Substances 0.000 claims 6
- -1 CD45R Proteins 0.000 claims 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- 102100022749 Aminopeptidase N Human genes 0.000 claims 4
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 4
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 4
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 108010029697 CD40 Ligand Proteins 0.000 claims 3
- 102100032937 CD40 ligand Human genes 0.000 claims 3
- 210000003038 endothelium Anatomy 0.000 claims 3
- 210000000981 epithelium Anatomy 0.000 claims 3
- 231100000167 toxic agent Toxicity 0.000 claims 3
- 239000003440 toxic substance Substances 0.000 claims 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims 2
- 102100032768 Complement receptor type 2 Human genes 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 claims 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 2
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 claims 2
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 claims 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 2
- 102000010787 Interleukin-4 Receptors Human genes 0.000 claims 2
- 108010038486 Interleukin-4 Receptors Proteins 0.000 claims 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 claims 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 2
- 102000010782 Interleukin-7 Receptors Human genes 0.000 claims 2
- 108010038498 Interleukin-7 Receptors Proteins 0.000 claims 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 2
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 2
- 102000003729 Neprilysin Human genes 0.000 claims 2
- 108090000028 Neprilysin Proteins 0.000 claims 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 210000003714 granulocyte Anatomy 0.000 claims 2
- 210000003630 histaminocyte Anatomy 0.000 claims 2
- 210000001821 langerhans cell Anatomy 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 102100032912 CD44 antigen Human genes 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 231100000617 superantigen Toxicity 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Abstract
The invention concerns medicaments containing antibodies which have at least one specificity and detect the MHCII antigen of a patient to be treated. The invention further concerns antibodies with two or more specificities which detect the MHCII antigen of a patient, and diagnostic compositions containing these antibodies.
Claims
1. Arzneimittel, enthaltend Antikörper mit zwei oder mehr Spezifitäten, wobei mindestens eine Spezifität das MHCII-Antigen eines zu behandelnden Patienten erkennt, und gegebenenfalls einen pharmazeutisch verträglichen Trägerstoff .A pharmaceutical composition containing antibodies having two or more specificities, wherein at least one specificity recognizes the MHCII antigen of a patient to be treated, and optionally a pharmaceutically acceptable carrier.
2. Arzneimittel nach Anspruch 1, wobei der Antikörper min¬ destens eine Spezifität aufweist, die ein Antigen er¬ kennt, das auf Leukämiezellen, Zellen der Hämatopoese oder entarteten Zellen des Epithels oder Endothels ex- primiert wird.2. The pharmaceutical composition according to claim 1, wherein the antibody has at least one specificity which detects an antigen which is expressed on leukemia cells, hematopoietic cells or degenerate cells of the epithelium or endothelium.
3. Arzneimittel nach Anspruch 2, wobei es sich bei dem Antigen um eines der folgenden Antigene handelt: CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD10, CDU, CDllb, CD13, CD14, CD19, CD20, CD21, CD22, CD23 , CD24 , CD30, CD33, CD37, CD40, CD40L, CD41, CD44 CD44v3, CD44v6, CD45R, CD56, CD71, B220, Ig-Idiotyp, einen IL-2-Rezep- tor, einen IL-6-Rezeptor oder ein tumorassoziiertes Antigen.3. Medicament according to claim 2, wherein the antigen is one of the following antigens: CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD10, CDU, CDIIb, CD13, CD14, CD19, CD20, CD21, CD22, CD23, CD24, CD30, CD33, CD37, CD40, CD40L, CD41, CD44 CD4v3, CD44v6, CD45R, CD56, CD71, B220, Ig idiotype, an IL-2 receptor, an IL-6 Receptor or a tumor-associated antigen.
4. Arzneimittel nach einem der Ansprüche 1 bis 3 , wobei der Antikörper mindestens eine Spezifität aufweist, die ein Antigen auf einer Effektorzelle erkennt.4. The pharmaceutical composition according to any one of claims 1 to 3, wherein the antibody has at least one specificity recognizing an antigen on an effector cell.
5. Arzneimittel nach Anspruch 4, wobei es sich bei den Ef¬ fektorzellen um T-Zellen, Granulocyten, Monocyten, Makrophagen, NK(natural killer) -Zellen, Mastzellen oder Langerhans-Zellen handelt.5. A pharmaceutical composition according to claim 4, wherein the Ef¬ fektorzellen are T cells, granulocytes, monocytes, macrophages, NK (natural killer) cells, mast cells or Langerhans cells.
6. Arzneimittel nach Anspruch 4 oder 5, wobei es sich bei dem Antigen auf der Effektorzelle um CD1, CD2, CD3 , CD4, CD5, CD8, CDllb, CD13 , CD16, CD28, CD32, CD33, CD40L, CD45R, CD56, CD64, einen IL-2-Rezeptor, einen IL-4-Re- zeptor, einen IL-7-Rezeptor oder um die γ-Kette eines IL-2-, IL-4- oder IL-7-Rezeptors handelt.6. Medicament according to claim 4 or 5, wherein the antigen on the effector cell to CD1, CD2, CD3, CD4, CD5, CD8, CDIIb, CD13, CD16, CD28, CD32, CD33, CD40L, CD45R, CD56, CD64 , an IL-2 receptor, an IL-4 receptor, zeptor, an IL-7 receptor or the γ chain of an IL-2, IL-4 or IL-7 receptor.
7. Arzneimittel nach einem der Ansprüche 1 bis 6, wobei der Antikörper eine Bindungsstelle aufweist, die in der Lage ist, spezifisch eine toxische Substanz zu binden.The pharmaceutical composition according to any one of claims 1 to 6, wherein the antibody has a binding site capable of specifically binding a toxic substance.
8. Arzneimittel nach einem der Ansprüche 1 bis 7, wobei der Antikörper oder das Antikörperfragment gekoppelt ist mit einem Enzym, einer toxischen Substanz, einem Radio- nuclid, Biotin oder einem Superantigen.8. A pharmaceutical composition according to any one of claims 1 to 7, wherein the antibody or the antibody fragment is coupled with an enzyme, a toxic substance, a radionuclid, biotin or a superantigen.
9. Arzneimittel nach einem der Ansprüche 1 bis 6, wobei der Antikörper als membranständiger Antikörper in einem Im- munoliposom vorliegt.9. Medicament according to one of claims 1 to 6, wherein the antibody is present as a membrane-bound antibody in an immunoliposome.
10. Arzneimittel nach einem der Ansprüche 1 bis 9, wobei es sich bei dem Antikörper um einen monoclonalen, polyclo- nalen, Chimären, rekombinanten, (halb-) synthetischen oder chemisch modifizierten Antikörper handelt oder um ein Fragment eines solchen Antikörpers.10. A pharmaceutical composition according to any one of claims 1 to 9, wherein the antibody is a monoclonal, polyclonal, chimeric, recombinant, (semi) synthetic or chemically modified antibody or a fragment of such an antibody.
11. Antikörper mit zwei oder mehr Spezifitäten, der minde¬ stens eine Antigenbindungsstelle aufweist, die spezi¬ fisch das MHCII-Antigen eines Patienten erkennt.11. Antibody having two or more specificities, which has at least one antigen binding site which specifically recognizes the MHCII antigen of a patient.
12. Antikörper nach Anspruch 11, der mindestens eine weitere Spezifität aufweist, die ein Antigen auf einer Effektor¬ zelle erkennt.12. An antibody according to claim 11, which has at least one further specificity which recognizes an antigen on an effector cell.
13. Antikörper nach Anspruch 12, wobei es sich bei dem Anti¬ gen der Effektorzelle um CD1, CD2, CD3 , CD4, CD5, CD6, CD7, CD8, CDllb, CD13, CD16, CD28, CD32, CD33, CD40L, CD45R, CD56, CD64 oder einen IL-2-Rezeptor handelt.13. The antibody according to claim 12, wherein the anti-effector effector cell to CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CDIIb, CD13, CD16, CD28, CD32, CD33, CD40L, CD45R, CD56, CD64 or an IL-2 receptor.
14. Antikörper nach Anspruch 12 oder 13 , wobei es sich bei den Effektorzellen um T-Zellen, Granulocyten, Monocyten, 2514. An antibody according to claim 12 or 13, wherein the effector cells are T cells, granulocytes, monocytes, 25
Makrophagen, NK(natural killer) -Zellen, Mast-Zellen oder Langerhans-Zellen handelt.Macrophages, NK (natural killer) cells, mast cells or Langerhans cells.
15. Antikörper nach einem der Ansprüche 11 bis 14, wobei der Antikörper mindestens eine weitere Spezifität aufweist, die ein Antigen erkennt, das auf Leukämiezellen, Zellen der Hämotopoese oder entarteten Zellen des Epithels oder Endothels exprimiert wird.The antibody of any one of claims 11 to 14, wherein the antibody has at least one additional specificity which recognizes an antigen expressed on leukemia cells, cells of the hemotopoiesis or degenerate cells of the epithelium or endothelium.
16. Antikörper nach Anspruch 15, wobei die weitere Spezifi¬ tät eines der folgenden Antigene erkennt:16. The antibody according to claim 15, wherein the further specificity of one of the following antigens recognizes:
CD1, CD2, CD3, CD4 , CD5, CD6, CD7, CD8, CD10, CDU, CDllb, CD13, CD14, CD19, CD20, CD21, CD22, CD23, CD24 , CD30, CD33, CD37, CD40, CD41, CD44v3 , CD44v6, CD45R, CD56, CD71, B220, Ig-Idiotyp, einen IL-2-Rezeptor, einen IL-6-Rezeptor oder ein tumorassoziiertes Antigen.CD1, CD2, CD3, CD4, CD5, CD6, CD7, CD8, CD10, CDU, CDIIb, CD13, CD14, CD19, CD20, CD21, CD22, CD23, CD24, CD30, CD33, CD37, CD40, CD41, CD44v3, CD44v6, CD45R, CD56, CD71, B220, Ig idiotype, an IL-2 receptor, an IL-6 receptor or a tumor associated antigen.
17. Antikörper nach einem der Ansprüche 11 bis 16, wobei es sich bei dem Antikörper um einen monoclonalen, rekom¬ binanten, (halb) -synthetischen oder chemisch modifizier¬ ten Antikörper oder um ein Fragment eines solchen Anti¬ körpers handelt .17. The antibody of claim 11, wherein the antibody is a monoclonal, recombinant, (semi) synthetic or chemically modified antibody or a fragment of such an antibody.
18. Antikörper nach einem der Ansprüche 11 bis 17, wobei der Antikörper gekoppelt ist mit einem Enzym, einer toxi¬ schen Substanz, einem Radionuclid, Biotin oder einem Su¬ perantigen.18. An antibody according to any one of claims 11 to 17, wherein the antibody is coupled with an enzyme, a toxic substance, a Radionuclid, biotin or a Su perantigen.
19. Verwendung eines Antikörpers nach einem der Ansprüche 11 bis 18 zur Herstellung eines Arzneimittels zur Immunthe¬ rapie.19. Use of an antibody according to any one of claims 11 to 18 for the manufacture of a medicament for immunotherapy.
20. Verwendung nach Anspruch 19, wobei es sich bei der Im¬ muntherapie um eine Therapie zur Behandlung von Tumoren handelt . 2620. Use according to claim 19, wherein the immunotherapy is a therapy for the treatment of tumors. 26
21. Verwendung nach Anspruch 20, wobei es sich bei dem Tumor um eine Leukämie handelt.21. Use according to claim 20, wherein the tumor is a leukemia.
22. Verwendung nach Anspruch 21, wobei es sich bei der Leu¬ kämie um ein B-Zell-Lymphom, ein Hodgkin-Lymphom, ein anaplastisches "large cell" Lymphom, eine adulte T-Zell- Leukämie oder ein Myelom handelt.22. Use according to claim 21, wherein the leukemia is a B-cell lymphoma, a Hodgkin's lymphoma, an anaplastic "large cell" lymphoma, an adult T-cell leukemia or a myeloma.
23. Verwendung nach Anspruch 20, wobei es sich bei dem Tumor um entartete Zellen des Epithels oder Endothels handelt.23. Use according to claim 20, wherein the tumor is degenerate cells of the epithelium or endothelium.
24. Verwendung nach Anspruch 19, wobei es sich bei der Im¬ muntherapie um eine Therapie zur Unterdrückung einer "Host-versus-Graft"-Reaktion handelt .24. Use according to claim 19, wherein the immunotherapy is a therapy for suppressing a host-versus-graft reaction.
25. Verwendung nach Anspruch 19, wobei es sich bei der Im¬ muntherapie um eine Therapie zur Unterdrückung einer Autoimmunreaktion handelt.25. Use according to claim 19, wherein the immunotherapy is a therapy for suppressing an autoimmune reaction.
26. Verwendung nach Anspruch 19, wobei es sich bei der Im¬ muntherapie um eine Therapie zur Auslösung einer Im- munsuppression handelt .26. Use according to claim 19, wherein the immunotherapy is a therapy for triggering an immunosuppression.
27. Verwendung eines monospezifischen Antiköpers der spezi¬ fisch das MHCII-Antigen eines zu behandelnden Patienten erkennt, oder eines Antikörpers nach einem der Ansprüche 1 bis 18 zur Herstellung eines Arzneimittels zur Elimi¬ nierung residueller Tumorzellen nach einer MHCII-inkom¬ patiblen Knochenmarktransplantation.27. Use of a monospecific antibody which specifically recognizes the MHCII antigen of a patient to be treated, or of an antibody according to one of claims 1 to 18 for the production of a medicament for elimination of residual tumor cells after an MHCII-incompatible bone marrow transplantation.
28. Diagnostische Zusammensetzung enthaltend einen monospe¬ zifischen Antikörper, der spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennt, oder einen Antikörper nach einem der Ansprüche 11 bis 18. 28. A diagnostic composition comprising a monospecific antibody which specifically recognizes the MHCII antigen of a patient to be treated, or an antibody according to any one of claims 11 to 18.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK96929318T DK0845998T3 (en) | 1995-08-25 | 1996-08-23 | Immunotherapy drugs containing antibodies that specifically recognize the MHCII antigen in a patient to be treated |
| DE59608213T DE59608213D1 (en) | 1995-08-25 | 1996-08-23 | MEDICINE FOR IMMUNOTHERAPY, CONTAINING ANTIBODIES THAT SPECIFICALLY DETECT THE MHCII ANTIGING OF A PATIENT TO BE TREATED |
| AT96929318T ATE208630T1 (en) | 1995-08-25 | 1996-08-23 | IMMUNOTHERAPY MEDICINAL PRODUCTS CONTAINING ANTIBODIES THAT SPECIFICALLY RECOGNIZE THE MHCII ANTIGEN OF A PATIENT TO BE TREATED |
| EP96929318A EP0845998B1 (en) | 1995-08-25 | 1996-08-23 | Immunotherapy medicaments containing antibodies which specifically detect the mhcii antigen of a patient to be treated |
| US09/029,369 US6294167B1 (en) | 1995-08-25 | 1996-08-23 | Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19531346.1 | 1995-08-25 | ||
| DE19531346A DE19531346A1 (en) | 1995-08-25 | 1995-08-25 | Medicines for immunotherapy, containing antibodies that specifically recognize the MHCII antigen of a patient to be treated |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997007819A1 WO1997007819A1 (en) | 1997-03-06 |
| WO1997007819B1 true WO1997007819B1 (en) | 1997-05-15 |
Family
ID=7770409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP1996/003733 WO1997007819A1 (en) | 1995-08-25 | 1996-08-23 | Immunotherapy medicaments containing antibodies which specifically detect the mhcii antigen of a patient to be treated |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6294167B1 (en) |
| EP (1) | EP0845998B1 (en) |
| AT (1) | ATE208630T1 (en) |
| DE (2) | DE19531346A1 (en) |
| DK (1) | DK0845998T3 (en) |
| ES (1) | ES2164914T3 (en) |
| PT (1) | PT845998E (en) |
| WO (1) | WO1997007819A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6368596B1 (en) * | 1997-07-08 | 2002-04-09 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| DE19937264A1 (en) * | 1999-08-06 | 2001-02-15 | Deutsches Krebsforsch | F¶v¶ antibody constructs |
| CA2391925A1 (en) * | 1999-11-18 | 2001-05-25 | Oxford Biomedica (Uk) Limited | Antibodies |
| AU2002340169A1 (en) * | 2001-10-11 | 2003-06-17 | Protein Design Labs Inc. | Identifying anti-tumor targets or agents by lipid raft immunization and proteomics |
| DE10261223A1 (en) * | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Increasing the immune response through substances that influence the function of natural killer cells |
| DK1874821T3 (en) | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Combination of antibodies with glycocorticoids to treat cancer |
| GB0509318D0 (en) * | 2005-05-06 | 2005-06-15 | Chiron Srl | TCR-independent activation of T cells |
| GB0512225D0 (en) * | 2005-06-16 | 2005-07-27 | Univ Sheffield | Immunoglobulin molecules |
| EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
| US7862813B2 (en) * | 2006-07-29 | 2011-01-04 | Bjork Jr Robert Lamar | Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug |
| GB0803076D0 (en) * | 2008-02-20 | 2008-03-26 | Univ Ghent | Mucosal Membrane Receptor and uses thereof |
| EP2241576A1 (en) | 2009-04-17 | 2010-10-20 | Trion Pharma Gmbh | Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells |
| EP3915999A1 (en) * | 2014-03-13 | 2021-12-01 | Universität Basel | Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein |
| BR112019010878A2 (en) | 2016-11-29 | 2019-10-01 | Lindhofer Horst | combination of multifunctional t-cell redirection antibodies with immune checkpoint modulators and their uses |
| KR20190118172A (en) | 2017-02-08 | 2019-10-17 | 드래곤플라이 쎄라퓨틱스, 인크. | Multispecific Binding Proteins for Activation of Natural Killer Cells and Their Therapeutic Uses in Cancer Treatment |
| JP2020508997A (en) | 2017-02-20 | 2020-03-26 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Proteins that bind to Her2, NKG2D and CD16 |
| EP3749346B1 (en) | 2018-02-08 | 2024-07-10 | Dragonfly Therapeutics, Inc. | Antibody variable domain combinations targeting the nkg2d receptor |
| SG11202007945UA (en) | 2018-02-20 | 2020-09-29 | Dragonfly Therapeutics Inc | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| EA202091888A1 (en) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR |
| WO2021226193A1 (en) | 2020-05-06 | 2021-11-11 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and clec12a |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0068790B1 (en) | 1981-06-25 | 1986-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Allele specific immunotherapeutic method and dosage form |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
-
1995
- 1995-08-25 DE DE19531346A patent/DE19531346A1/en not_active Ceased
-
1996
- 1996-08-23 EP EP96929318A patent/EP0845998B1/en not_active Expired - Lifetime
- 1996-08-23 ES ES96929318T patent/ES2164914T3/en not_active Expired - Lifetime
- 1996-08-23 WO PCT/EP1996/003733 patent/WO1997007819A1/en active IP Right Grant
- 1996-08-23 PT PT96929318T patent/PT845998E/en unknown
- 1996-08-23 US US09/029,369 patent/US6294167B1/en not_active Expired - Lifetime
- 1996-08-23 AT AT96929318T patent/ATE208630T1/en active
- 1996-08-23 DE DE59608213T patent/DE59608213D1/en not_active Expired - Lifetime
- 1996-08-23 DK DK96929318T patent/DK0845998T3/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1997007819B1 (en) | Immunotherapy medicaments containing antibodies which specifically detect the mhcii antigen of a patient to be treated | |
| Mason et al. | LGL-1: a non-polymorphic antigen expressed on a major population of mouse natural killer cells. | |
| Reinherz et al. | Antibody directed at a surface structure inhibits cytolytic but not suppressor function of human T lymphocytes | |
| Ciccone et al. | Self class I molecules protect normal cells from lysis mediated by autologous natural killer cells | |
| Weiss et al. | Requirement for the coexpression of T3 and the T cell antigen receptor on a malignant human T cell line. | |
| Bonnefoy et al. | The low-affinity receptor for IgE (CD23) on B lymphocytes is spatially associated with HLA-DR antigens. | |
| US5777084A (en) | Antibody BV10A4H2 specific for human FLT3/FLK2 receptor and mybridoma | |
| EP0403156B1 (en) | Improved monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use | |
| KR100426113B1 (en) | Usefulness in the diagnosis and treatment of T-cell antigens and T-cell mediated symptoms | |
| FI117900B (en) | A method of producing a cell which expresses chimeric receptors that restore cellular immunity and DNA and vector encoding the chimeric receptors | |
| EP2070948B1 (en) | Humanized Anti-CD4 antibody with immunosuppressive properties | |
| Schiller et al. | CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells | |
| US6294167B1 (en) | Pharmaceutical compositions for immunotherapy containing antibodies which specifically recognize the MHCII antigen of a patient to be treated | |
| Spertini et al. | Induction of human T cell proliferation by a monoclonal antibody to CD5. | |
| Pauza et al. | Unusual patterns of immunoglobulin gene rearrangement and expression during human B cell ontogeny: human B cells can simultaneously express cell surface kappa and lambda light chains. | |
| US20100015153A1 (en) | Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells and Antibodies That Identify the Same | |
| JPS6362518B2 (en) | ||
| Todd III et al. | A monoclonal antibody that blocks class II histocompatibility-related immune interactions | |
| EP0241811B1 (en) | Monoclonal antibodies against the human interleukin-2 receptor | |
| FI75598C (en) | Method for Preparation of a Monoclonal Antibody to a Human Thymocyte Antigen by a New Hybrid Cell Line. | |
| Dang et al. | FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation | |
| Alvarez-Vallina et al. | Delimitation of the proliferative stages in the human thymus indicates that cell expansion occurs before the expression of CD3 (T cell receptor). | |
| Braakman et al. | Expression of CD45 isoforms by fresh and activated human γδ T lymphocytes and natural killer cells | |
| Chayen et al. | Preparation and properties of a cytotoxic monoclonal rat anti-mouse Thy-1 antibody | |
| US6156882A (en) | Antibody 4G8B4B12 |